REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) will present multiple oral and poster abstracts at the ASGCT 2026 annual meeting in Boston, May 11–15, 2026.

Oral highlights include NAVXpress manufacturability advances and an encore of topline pivotal data for RGX-202 (Duchenne). Multiple posters cover NVG82, capsid engineering, reduced liver/DRG transduction, and single-nuclei transcriptomics.

News Market Reaction – RGNX

+1.96%

1 alert

+1.96% Session close to close

$537.85M Market Cap

0.0x Rel. Volume

In the May 7 session, RGNX gained 1.96%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines REGENXBIO’s broad presence at ASGCT 2026, featuring an encore presentatio...

Analysis

This announcement outlines REGENXBIO’s broad presence at ASGCT 2026, featuring an encore presentation of RGX-202 pivotal topline data, NAVXpress manufacturing advances, and multiple posters on NVG82 and other next-generation AAV technologies. It builds on a series of recent RGX-202 and pipeline updates over early 2026. Investors may watch how detailed data, particularly around Duchenne muscular dystrophy and engineered capsids, evolve relative to earlier interim results and how these developments interact with existing financing and regulatory disclosures.

Key Figures

ASGCT 2026 dates: May 11–15, 2026 Price move: 10.85% Trading volume: 1,455,945 shares +5 more

8 metrics

ASGCT 2026 dates May 11–15, 2026 American Society of Gene & Cell Therapy Annual Meeting schedule

Price move 10.85% RGNX 24h price change prior to ASGCT presentation news

Trading volume 1,455,945 shares Today’s volume vs 20-day average of 613,565 shares

Poster 1031 session time 5:00–6:30pm ET NVG82 retinal gene transfer poster on May 12, 2026

Oral RGX-202 slot 4:30–4:45pm ET RGX-202 Duchenne pivotal topline encore on May 15, 2026

Shelf capacity $300,000,000 Maximum aggregate offering amount under S-3 shelf filed November 26, 2025

ATM program size $150 million Common stock registered for at-the-market offering in 424B5 dated February 12, 2026

2025 revenue $170.4M Full-year 2025 revenue from March 5, 2026 8-K

Historical Context

5 past events · Latest: May 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 06	Webcast & topline preview	Positive	+10.8%	Announced May 14 webcast for RGX-202 pivotal topline data and Q1 2026 results.
Mar 11	Clinical data update	Positive	-5.3%	Reported positive interim Phase I/II AFFINITY DUCHENNE RGX-202 data with improved function.
Mar 05	Earnings & pipeline update	Negative	-4.6%	Detailed higher 2025 revenue and narrowed losses alongside FDA holds and a CRL.
Mar 04	Conference presentations	Positive	+5.2%	Announced multiple RGX-202 presentations at the 2026 MDA Clinical & Scientific Conference.
Mar 02	Investor conferences	Neutral	+2.2%	Outlined participation in several March 2026 healthcare investor conferences with webcasts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

RGNX often reacts positively to event and presentation updates, but has shown at least one divergence where strong clinical data coincided with a price decline.

Recent Company History

Recent news for RGNX has centered on RGX-202 for Duchenne muscular dystrophy and late-stage pipeline progress. A March 11, 2026 release reported positive interim Phase I/II AFFINITY DUCHENNE data, while a March 5, 2026 update detailed $170.4M in 2025 revenue, a narrowed $193.9M net loss, and regulatory setbacks for RGX-111 and RGX-121. Conference and presentation announcements on March 2-4, 2026 generally coincided with positive moves, consistent with today’s ASGCT-focused news and the 10.85% gain after the May 6 webcast notice.

Key Terms

aav, suprachoroidal, capsid, gene therapy, +4 more

8 terms

aav medical

"Session: AAV Critical Quality Attributes"

AAV is a small, generally harmless virus repurposed by researchers as a delivery vehicle to insert therapeutic genes into human cells; think of it as a postal service that carries corrective DNA to specific tissues. Investors pay attention because AAV-based treatments can offer durable, potentially one-time cures that command high prices, but they also carry development, manufacturing and regulatory risks that can sharply influence a biotech company’s value.

suprachoroidal medical

"enhanced outer retinal gene transfer when administered in the suprachoroidal space"

Suprachoroidal describes delivering or placing a drug, device, or treatment into the thin space between the eye’s choroid (the layer rich in blood vessels) and the outer white layer called the sclera. Investors care because this targeted route can concentrate therapy where it’s needed, potentially improving effectiveness, reducing side effects, enabling longer dosing intervals or easier administration—factors that influence clinical success, regulatory approval and commercial value.

capsid medical

"NVG82, a capsid engineered for enhanced outer retinal gene transfer"

A capsid is the protein shell that encases a virus’s genetic material, like the hard case around a fragile object. For investors, the capsid matters because its shape and chemistry determine how a virus or viral vector behaves—affecting vaccine effectiveness, gene therapy delivery, immune reactions, manufacturing complexity, and related patents, all of which can influence the commercial prospects and regulatory path of biotech products.

gene therapy medical

"next generation gene therapy program for Duchenne muscular dystrophy"

Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.

transduction medical

"Route-Dependent Ocular Transduction in Rodent Models by the Novel AAV Capsid NVG82"

Transduction is the process by which genetic instructions are delivered into a cell using a carrier, often a harmless virus, so the cell can read and act on those instructions. For investors, transduction is central to many gene and cell therapies because it determines how effectively and safely a treatment reaches target cells—affecting clinical success, manufacturing complexity, regulatory review, and commercial viability, much like the reliability of a delivery service impacts product performance.

single-nuclei transcriptomic medical

"Single-nuclei transcriptomic analysis of skeletal muscle mRNA in mdx mice"

A lab technique that reads which genes are active inside individual cell nuclei, producing a detailed map of cellular behavior much like reading each household’s mail to see what people are talking about. It matters to investors because it reveals precise disease mechanisms, potential drug targets and patient subgroups that bulk tests miss, helping companies de‑risk and prioritize research programs and improve chances of successful therapies.

mdx mice medical

"skeletal muscle mRNA in mdx mice treated with RGX-202"

Mdx mice are lab-bred mice that carry a genetic defect causing loss of dystrophin, a protein that helps muscle cells stay intact; they serve as a standard animal model for Duchenne muscular dystrophy. For investors, positive results in mdx mice act like a crash-test for experimental therapies—providing early, live-animal evidence that a treatment can improve muscle structure or function and helping to de-risk and prioritize funding before costly human trials.

micro-dystrophin medical

"RGX-202, an AAV vector encoding micro-dystrophin"

Micro-dystrophin is a shortened, engineered version of dystrophin—the large muscle protein missing or faulty in Duchenne muscular dystrophy—designed to restore basic muscle function when delivered to cells. Investors track micro-dystrophin because it is the active ingredient in several gene therapy candidates; its ability to reach muscles, produce a stable protein and show clinical benefit drives trial success, regulatory approval chances and eventual commercial value, much like a repaired engine part determining a car’s performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., May 7, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 2026 American Society of Gene & Cell Therapy Annual Meeting ("ASGCT 2026") taking place May 11-15, 2026, in Boston, Massachusetts. 

Oral Presentations:
The oral presentations include an overview of recent advancements in production titer and product quality achieved through REGENXBIO's NAVXpress® manufacturing platform and an encore presentation of topline pivotal data from RGX-202, the company's next generation gene therapy program for Duchenne muscular dystrophy.

Title: Advancing AAV manufacturability toolbox for early programs and beyond
Presenter: Metewo Selase Kosi Enuameh, Ph.D., Associate Director, Vector Core at REGENXBIO
Presentation: 266
Session: AAV Critical Quality Attributes
Date/Time: Thursday, May 14, 8:45 – 9:00am ET
Location: MCEC Room 204AB (Level 2)

Title: RGX-202: Investigational gene therapy for Duchenne Muscular Dystrophy
Presenter: Aravindhan Veerapandiyan, M.D., Director of the Comprehensive Neuromuscular Program, PPMD Certified Duchenne Care Center, and Co-Director of the Muscular Dystrophy Association Care Center at Arkansas Children's Hospital
Presentation: 506
Session: In vivo clinical trials in eye and muscle disorders
Date/Time: Friday, May 15, 4:30 – 4:45pm ET
Location: MCEC Room 210ABC (Level 2)

Poster Presentations:
These presentations demonstrate REGENXBIO's continued leadership in the discovery and advancement of next-generation gene therapies for rare and retinal diseases, and highlight the company's unique capsid engineering and translational capabilities.

Title: NVG82, a capsid engineered for enhanced outer retinal gene transfer when administered in the suprachoroidal space, demonstrates superior on-target activity compared to AAV8
Poster: 1031
Presenter: Brendan Lilley, Ph.D., Director of Ophthalmology Research, REGENXBIO
Location: MCEC Exhibit and Poster Hall (Halls B2-C, Exhibit level)
Date/Time: Tuesday, May 12, 5:00 – 6:30pm ET

Title: Examination of Route-Dependent Ocular Transduction in Rodent Models by the Novel AAV Capsid NVG82
Poster: 3031
Presenter: Huzzatul Mursalin, Ph.D., Scientist II, Gene Therapy Research, REGENXBIO
Location: MCEC Exhibit and Poster Hall (Hall B2-C, Exhibit level)
Date/Time: Thursday, May 14, 5:00 – 6:30pm ET

Title: Development of an engineered hybrid AAV with reduced liver and DRG transduction and high productivity
Poster: 3030
Presenter: Samantha Yost, Ph.D., Senior Scientist, Gene Therapy Research, REGENXBIO
Location: MCEC Exhibit and Poster Hall (Hall B2-C, Exhibit level)
Date/Time: Thursday, May 14, 5:00 – 6:30pm ET

Title: Single-nuclei transcriptomic analysis of skeletal muscle mRNA in mdx mice treated with RGX-202, an AAV vector encoding micro-dystrophin
Poster: 3499
Presenter: Justin Glenn, Ph.D., Principal Scientist, Gene Therapy Research, REGENXBIO
Location: MCEC Exhibit and Poster Hall (Hall B2-C, Exhibit level)
Date/Time: Thursday, May 14, 5:00 – 6:30pm ET

All presentations will be available on the Publications page of REGENXBIO's website, www.regenxbio.com.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-society-of-gene--cell-therapy-2026-annual-meeting-302765129.html

SOURCE REGENXBIO Inc.

FAQ

When will REGENXBIO (RGNX) present oral data on RGX-202 at ASGCT 2026?

REGENXBIO will present an encore of RGX-202 topline pivotal data on May 15, 2026, at 4:30–4:45pm ET. According to the company, the talk appears in Session 506 on in vivo clinical trials in eye and muscle disorders at MCEC Room 210ABC.

What NAVXpress manufacturing updates will REGENXBIO (RGNX) share at ASGCT 2026?

REGENXBIO will present NAVXpress improvements for production titer and product quality on May 14, 2026, at 8:45–9:00am ET. According to the company, this oral presentation is in the AAV Critical Quality Attributes session by Metewo Selase Kosi Enuameh.

Which REGENXBIO (RGNX) posters cover retinal capsid NVG82 at ASGCT 2026?

Two posters discuss NVG82, including superior outer retinal gene transfer and route-dependent ocular transduction on May 12 and May 14, 2026. According to the company, both posters are in the MCEC Exhibit and Poster Hall during scheduled poster sessions.

Will REGENXBIO (RGNX) present data on reducing liver and DRG transduction?

Yes. A poster titled 'engineered hybrid AAV with reduced liver and DRG transduction and high productivity' is scheduled for May 14, 2026 from 5:00–6:30pm ET. According to the company, Samantha Yost will present in the Exhibit and Poster Hall.

Where can investors access REGENXBIO (RGNX) ASGCT 2026 presentations after the meeting?

All REGENXBIO presentations will be posted on the company's Publications page after ASGCT 2026. According to the company, digital copies and materials will be available via the REGENXBIO website for investor and public access.